Proton pump inhibitors are used to treat gastro-oesophageal reflux and peptic ulcers.
Gastro-esophageal reflux is a common condition in pregnancy.
Human pregnancy experience with lansoprazole or pantoprazole is very limited.
More data exist on the safety of omeprazole in pregnancy.
Dr Ornoy and colleagues from Jerusalem, Israel undertook a study in order to assess the safety of proton pump inhibitors in pregnancy.
The research team designed a multicenter (n = 8), prospective, controlled study of the European Network of Teratology Information Services.
The researchers compared the rate of major anomalies between pregnant women exposed to omeprazole, lanzoprazole, or pantoprazole and a control group counseled for non-teratogens.
| Rate of major congenital anomalies did not differ between the exposed and control groups [omeprazole 9 of 249 vs controls 30 of 792]|
|Alimentary Pharmacology and Therapeutics|
The researchers followed up a total of 295 pregnancies exposed to omeprazole [233 in the first trimester (T1)], 62 to lansoprazole (55 in T1) and 53 to pantoprazole (47 in T1).
The research team then compared pregnancy outcome to that of 868 European Network of Teratology Information Services controls.
The researchers found that the rate of major congenital anomalies did not differ between the exposed and control groups [omeprazole 9 of 249, lansoprazole 2 of 51, and pantoprazole 1 of 48 vs. controls 30 of 792].
The team found no differences when exposure was limited to the first trimester after exclusion of genetic, cytogenetic or infectious anomalies.
Dr Ornoy commented, "This study suggests that proton pump inhibitors do not represent a major teratogenic risk in humans."